Approaches to reduce DAPK1 activity have demonstrated benefit in animal models of stroke, Alzheimer’s disease, Parkinson’s disease, and chronic stress, indicating that DAPK1 may be a novel target for neuroprotection. This evidence concerns the gene DAPK1 and early-onset autosomal dominant Alzheimer disease.